Antigen-Binding Polypeptides Site-Specific PEGylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modifying proteins with poly(ethylene glycol) (PEG) derivatives face challenges such as non-specific attachment, instability, toxicity, and loss of biological activity due to indiscriminate attachment to reactive sites, which limits their therapeutic potential.
Innovation Solution
Incorporation of non-naturally encoded amino acids into proteins allows for the introduction of chemical functional groups that enable selective and stable coupling of PEG polymers, avoiding undesired side reactions and preserving biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If PEG derivatives are attached to proteins using conventional methods, then solubility and stability are improved, but non-specific attachment and loss of biological activity occur
Solution Approach 1:
The patent introduces non-naturally encoded amino acids with unique reactive groups at specific locations within the protein sequence. This allows PEG attachment to occur only at predetermined sites rather than randomly across all reactive amino acids, achieving site-specific modification while maintaining overall protein stability and biological activity
Solution Approach 2:
The non-naturally encoded amino acids serve as intermediary structures that mediate between the protein and PEG derivative. These amino acids contain unique chemical groups (such as keto, azide, or alkyne groups) that act as selective attachment points, enabling controlled PEGylation without affecting other protein regions
2Duration of action of stationary object
If PEG derivatives are attached to increase therapeutic half-life, then circulation time is extended, but toxicity and immunogenicity increase
Solution Approach 1:
By limiting PEG attachment to specific non-critical regions of the protein through non-naturally encoded amino acids, the patent minimizes disruption to immunogenic epitopes and other functionally important regions. This localized approach extends half-life while reducing the risk of inducing immune responses
Solution Approach 2:
The patent allows control over the degree of PEGylation by adjusting parameters such as the number of non-naturally encoded amino acids introduced and the molecular weight of PEG derivatives used. This enables optimization of the balance between extended circulation time and reduced immunogenicity
3Quantity of substance
If conventional PEGylation methods are used to improve solubility, then protein solubility increases, but biological activity is lost
Solution Approach 1:
The patent attaches PEG derivatives only at specific sites introduced via non-naturally encoded amino acids, ensuring that critical functional regions and binding interfaces remain unaffected. This maintains biological activity while achieving the solubility enhancement benefits of PEGylation
Solution Approach 2:
The non-naturally encoded amino acids are incorporated into the protein sequence during synthesis, preparing specific attachment sites in advance. This preliminary placement ensures that subsequent PEGylation occurs only at predetermined locations that are unlikely to interfere with biological function
Data Source
AI summary
Novel antigen-binding polypeptides (ABP) and uses thereof are provided.